logo
CPG, Wine & Spirits Veteran Seth Kaufman Joins PMI U.S. as Chief Commercial Officer as Company Expands Smoke-Free Portfolio to Meet Growing Demand

CPG, Wine & Spirits Veteran Seth Kaufman Joins PMI U.S. as Chief Commercial Officer as Company Expands Smoke-Free Portfolio to Meet Growing Demand

STAMFORD, Conn.--(BUSINESS WIRE)--Mar 28, 2025--
PMI U.S., which is on a mission to improve public health by providing smoke-free alternatives to legal-age nicotine consumers, announced today that Seth Kaufman will become its U.S. chief commercial officer. Kaufman, a veteran of the consumer packaged goods (CPG) industry, including wine & spirits, will lead commercial strategy for smoke-free products, including ZYN nicotine pouches, General snus and the IQOS heat-not-burn device. He will report to PMI U.S. CEO Stacey Kennedy as a member of the U.S. executive team.
This press release features multimedia. View the full release here:
Seth Kaufman, U.S. Chief Commercial Officer, PMI
'As we invest in U.S. manufacturing and create new American jobs to meet the growing demand for our smoke-free products, Seth's expertise in commercial marketing and in leading transformative growth strategies will accelerate our mission to improve public health by providing the 45 million legal-age nicotine consumers in the U.S. — 30 million of whom still smoke traditional cigarettes — with better alternatives,' said PMI U.S. CEO Stacey Kennedy.
PMI entered the U.S. market for the first time in late 2022 acquiring Swedish Match, which has sold ZYN nicotine pouches in the U.S. for more than a decade through its U.S. division. In January 2025, following extensive scientific review, the U.S. Food and Drug Administration (FDA) authorized the marketing of 20 ZYN nicotine pouch products, finding these products to be 'appropriate for the protection of public health.' ZYN is the first and only FDA-authorized nicotine pouch. PMI U.S. affiliates are also introducing IQOS, the first FDA-authorized device that heats tobacco instead of burning it, significantly reducing exposure to harmful chemicals compared to traditional cigarettes.
In 2024, PMI U.S. affiliates announced investment in a new facility in Aurora, Colorado, to produce ZYN nicotine pouches, along with a significant expansion of the Swedish Match facility in Owensboro, Kentucky, that currently makes ZYN.
Kaufman brings nearly 30 years of experience in growing CPG businesses in the U.S. He spent nearly two decades moving up the ranks at PepsiCo, including as chief marketing officer and president of PepsiCo North America Nutrition and The Hive. He was president & CEO of LVMH Moët Hennessy North America before leading an enterprise-wide restructuring process at Vintage Wine Estates in California as president & CEO. Kaufman holds an MBA from the University of Michigan Ross School of Business. Business Insider named him to its Top 50 Most Innovative CMOs in the World list, and the American Advertising Federation elected him to its Hall of Achievement.
Kaufman begins his new role on March 31, 2025, and will be based at PMI's corporate headquarters in Stamford, Connecticut.
Philip Morris International: Delivering a smoke-free future
Philip Morris International Inc. (PMI) is headquartered in Stamford, Conn., and its U.S. affiliates have more than 2,500 employees. PMI's U.S. affiliates are on a mission to improve public health by providing the nearly 30 million legal-age U.S. consumers who smoke and other legal-age nicotine consumers with innovative products that are better alternatives to continued smoking. Since 2008, PMI's affiliates have invested $14 billion globally to develop, scientifically substantiate and commercialize innovative smoke-free products. PMI's U.S. affiliates operate smoke-free product manufacturing facilities, including the Swedish Match North America Owensboro, Ky., plant that makes ZYN nicotine pouches and a facility in Wilson, N.C., that produces HEETS, the consumable for the IQOS heated tobacco device. Swedish Match North America has a regional office in Richmond, Va.
U.S. marketing practices support 21+ access only
PMI's U.S. affiliates are committed to responsible marketing practices focused on limiting access to adults 21+ years of age and older. PMI's U.S. affiliates do not use social media influencers in the U.S. or people under the age of 35 in marketing materials. They also employ independent age-verification systems like 'Double Verify' to direct digital advertising to those over 21, and owned digital platforms are age-gated at the point of access and restricted to current nicotine users of legal age. Swedish Match North America is a Manufacturer Advisory Council member of the We Card Program, a national nonprofit serving retailers of age-restricted products, and a founding board member and investor in TruAge ®, a free retail technology that provides stores a more accurate way of age verification, including the ability to detect fake IDs to ensure 21+ access only.
Commitment to corporate social responsibility
PMI's U.S. affiliates have contributed approximately $25 million to charitable causes since 2022 and look to accelerate and amplify the good work of organizations already active within communities through both financial contributions and volunteering. Three key focus areas include supporting military veterans and their families, local economic development and disaster prevention and relief. PMI's U.S. affiliates also helped form 'United to Safeguard America from Illegal Trade' (USA-IT), a coalition of nearly 100 national and state brand enforcement experts, law enforcement agencies, academics and leading business organizations working to combat illegal trade. USA-IT has trained more than 36,000 law enforcement officials.
Travis Parman
INDUSTRY KEYWORD: TOBACCO RETAIL
SOURCE: Philip Morris International Inc.
Copyright Business Wire 2025.
PUB: 03/28/2025 09:27 AM/DISC: 03/28/2025 09:27 AM

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

White House tries to water down Russia sanctions
White House tries to water down Russia sanctions

Yahoo

time28 minutes ago

  • Yahoo

White House tries to water down Russia sanctions

Donald Trump is pressuring a US senator to weaken a Bill that would impose sweeping sanctions on Russia. White House officials hoping to mend relations with Moscow have been quietly contacting senator Lindsey Graham's office urging him to water down his Bill, which aims to cripple Vladimir Putin with huge sanctions. The Bill, backed by nearly the entire Senate, would impose 500 per cent tariffs on countries that continue to buy Russian oil and gas, which bankrolls Putin's war effort. Officials have been demanding the Bill include waivers that would allow Mr Trump to choose who or what was sanctioned, congressional aides told the Wall Street Journal. Other attempts to weaken the legislation include softening the language, replacing 'shall' with 'may' to avoid making the reprimands mandatory. Removing the mandatory nature of the sanctions would render the Bill effectively toothless and do little to hamper Putin's war machine, aides fear. 'We're moving ahead and the White House is included in our conversations,' Richard Blumenthal, senator and lead Democratic co-sponsor of the Bill, told the paper. Russia's war effort is funded by fossil-fuel exports. Moscow has adapted to existing sanctions with relative ease, turning to North Korea and China for support. Fearing the impact on pump prices, Joe Biden, former president, was unwilling to crack down on Russian energy exports. Mr Trump, has threatened to impose sanctions on Ukraine, as well as Russia, if the two sides fail to reach a peace agreement. 'Any sanction package must provide complete flexibility for the president to continue to pursue his desired foreign policy,' a White House official said. They added that the constitution 'vests the president with the authority to conduct diplomacy with foreign nations'. Speaking in the Oval Office alongside Friedrich Merz, German chancellor, on Thursday, the US president said that the Bill should not move forward without his express approval. 'They'll be guided by me. That's how it's supposed to be,' he told reporters. 'They're waiting for me to decide on what to do.' Last week, Mr Graham and Mr Blumenthal visited Ukraine where they applauded the country's drone attack that destroyed 40 aircraft deep inside Russian territory. However, they were ridiculed and accused of 'stirring up' the conflict by key allies of Mr Trump, including Steve Bannon. 'By trying to engage Putin – by being friendly and enticing – it's become painfully clear [Putin's] not interested in ending this war,' Mr Graham said earlier this week. '[Putin] needs to see and hear that message as well from us, from the American people,' said Mr Blumenthal. Both said that failing to act now could pull the US deeper into the conflict later. If Putin isn't stopped in Ukraine, Mr Blumenthal said, Nato treaty obligations could compel US troops into battle. Earlier this week, Russian negotiators tabled a long memorandum, resembling a complete capitulation for Ukraine, in a second round of direct talks with Kyiv in Istanbul. They demanded Ukraine must withdraw its troops from four eastern regions that Russia only partially occupies and that international recognition of Russian sovereignty over them and Crimea must be granted. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom

Yahoo

time36 minutes ago

  • Yahoo

3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom

Over the past year, advancements in artificial intelligence (AI) and predictive analytics have rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and personalized treatment. AI-powered devices now process large datasets in real time, delivering accurate predictions and actionable insights. Predictive analytics supports early disease detection, risk assessment, maintenance optimization, and cost reduction. According to a January 2025 report, genAI is already generating synthetic medical images, simulating disease progression, and accelerating drug discovery. However, it also introduces new regulatory challenges around safety, transparency, and data integrity. In response, the FDA is implementing a Total Product Lifecycle (TPLC) oversight model with a risk-based approach and enhanced post-market monitoring. Going by data, global AI in the healthcare market is projected to witness a CAGR of 38.5% from 2024 to 2030. However, a deteriorating geopolitical situation, tariffs and supply chain bottlenecks, resulting in a tough situation related to raw material and labor costs, freight charges, as well as healthcare staffing shortages, have put the industry in a tight spot again. Meanwhile, industry players like Penumbra PEN, Integer Holdings ITGR and AngioDynamics ANGO have adapted well to changing consumer preferences and have been witnessing an uptrend in their stock prices. Industry Description The Zacks Medical - Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. This FDA-regulated sector encompasses a vast array of products, from transcatheter valves and orthopedic devices to advanced imaging equipment and robotics. Recent trends highlight the integration of AI in diagnostics, the expansion of telemedicine, the rise of robotic-assisted surgeries, and developments in 3D printing, continuous glucose monitoring systems, gene editing, and nanomedicine. The emergence of generative AI is also reshaping MedTech, prompting the FDA to adopt a TPLC regulatory approach. 3 Trends Shaping the Future of the Medical Instruments Industry Over the past couple of years, there has been a significant increase in the adoption of genAI within the medical instruments space, with 'hyper-personalization' being the primary feature of genAI-driven treatment options. Added to this, genAI is rapidly paving the way for efficient operational management within the industry. GenAI, while analyzing vast and complex genetic and molecular data, is expected to help healthcare reach new heights in terms of predictive treatment options and smart hospital systems. A December 2024 report says that global genAI in the healthcare market was valued at $1.8 billion in 2023 and is expected to witness a CAGR of 33.2% from 2024 to 2032. Rapid advancement in deep learning and natural language processing, increasing demand for personalized treatment, growing investment in healthcare AI and rising healthcare data volumes are the major growth factors. This apart, the application of AI in the diagnostics space is growing enormously with the market expected to witness a CAGR of 24.6% by 2034.: The medical instruments space has been benefiting from the ongoing merger and acquisition (M&A) trend. It is a known fact that smaller and mid-sized industry players attempt to compete with the big shots through consolidation. The big players attempt to enter new markets through a niche product. Going by a J.P. Morgan report of 2025, in 2024, MedTech acquisition activity exceeded the previous two years in both deal count and total announced value. A total of 305 M&A transactions were announced, totaling over $63.1 billion for companies in medical devices, diagnostics, therapeutic digital health and commercial research tools, up from 134 deals in 2023. In 2025 so far, notable examples of M&A include Stryker's $4.9 billion acquisition of Inari Medical to expand its peripheral thrombectomy portfolio, Thermo Fisher's $4.1 billion purchase of Solventum's Purification & Filtration business, and Boston Scientific's $664 million acquisition of Bolt Medical to strengthen its position in intravascular lithotripsy solutions.: Per IMF's April 2025 World Economic Outlook, global growth is expected to remain lackluster over the next couple of years. At 2.8% in 2025 and 3.0% in 2026, the forecasts for growth are below the historical (2000–19) average of 3.7%. A few countries, especially low-income developing countries, have seen sizable downside growth revisions, often as a result of increased conflicts and recent tariff shocks. The good news is that global headline inflation is expected to decline to 4.3% in 2025 and to 3.6% in 2026, with advanced economies reaching the targets sooner than emerging market and developing economies. However, the IMF apprehends that the current policy-generated disruptions to the ongoing disinflation process could interrupt the pivot to easing monetary policy, with implications for fiscal sustainability and financial stability. Further, there are chances of higher nominal wage growth, which in some cases reflects the catch-up of real wages, accompanied by weak productivity, which could make it difficult for firms to moderate price increases, especially when profit margins are already squeezed. Zacks Industry Rank Indicates Dull Prospects The Zacks Medical Instruments industry's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates gloomy near-term prospects. The industry, housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #131, which places it in the bottom 46% of 244 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook. But it's worth taking a look at the industry's shareholder returns and current valuation first. Industry Underperforms S&P 500, Outperforms Sector The industry has underperformed the Zacks S&P 500 composite but outperformed the sector in the past year. The industry has declined 12.7% compared with the broader sector's decline of 14.7%. The S&P 500 has surged 12.8% in a year. One-Year Price Performance Industry's Current Valuation On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 29.04X compared with the broader industry's 19.18X and the S&P 500's 21.83X. Over the past five years, the industry has traded as high as 40.60X, as low as 25.62X and at the median of 32.52X, as the charts show below. 3 Stocks to Buy Right Now Integer Holdings: Plano, TX-based Integer Holdings is a medical device contract development and manufacturing organization. Its strategic focus on portfolio optimization, including the divestiture of its Non-Medical business, supports its long-term inorganic growth plans. Integer Holdings has established a solid position in the MedTech industry and continues to invest in research and product development, which bodes well for innovation and future revenue growth. The Zacks Consensus Estimate for this Zacks Rank #1 (Strong Buy) company's 2025 sales is pegged at $1.87 billion, indicating a 7.7% rise from 2024. The consensus mark for Integer Holdings' 2025 EPS is pegged at $6.33, indicating an increase of 19.4% from 2024. AngioDynamics: Headquartered in Latham, NY, AngioDynamics' solid prospects with NanoKnife and an increased focus on cancer treatment markets are encouraging. The company boasts a robust product pipeline and strong momentum in geographic expansion. Continued strong sales of Auryon, AlphaVac, and NanoKnife products further strengthen AngioDynamics' outlook. The consensus estimate for this Zacks Rank #1 company's fiscal 2026 sales is pegged at $305 million, indicating a 6.3% rise from fiscal 2025. The consensus mark for AngioDynamics' fiscal 2026 EPS is pegged at a loss of 24 cents, indicating an improvement of 14.9% from the year-ago period figure. Penumbra: Alameda, CA-based Penumbra's consistent revenue growth momentum is being driven by strong patient outcomes with Lightning Flash 2.0, Lightning Bolt 7 and RED 72. The company's vascular and neuro businesses are showing encouraging growth trends. Penumbra's Immersive Healthcare business too is making progress. The Zacks Consensus Estimate for Penumbra's 2025 sales is pegged at $1.35 billion, indicating a 13.4% rise from 2024. The consensus mark for Penumbra's 2025 EPS is pegged at $3.72, indicating an improvement of 67.6% from the year-ago period figure. Penumbra has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trump signs new executive orders intended to make flying cars a reality, slash flight times
Trump signs new executive orders intended to make flying cars a reality, slash flight times

Yahoo

timean hour ago

  • Yahoo

Trump signs new executive orders intended to make flying cars a reality, slash flight times

President Donald Trump signed three new executive orders Friday aimed at accelerating American drone innovation and supersonic air travel, while also restoring security to American airspace. The three orders will be critical to American safety and security, White House officials involved in the drafting of the orders indicated, particularly in light of major worldwide events coming to the United States in the next few years, such as the World Cup and the Olympics. In addition to bolstering safety and security, the new orders will also spur greater innovation in the aerospace and drone sectors, something White House officials said has been stifled in recent years as a result of burdensome regulations. "Flying cars are not just for the Jetsons," Michael Kratsios, a lead tech policy advisor at the White House said. "Since the beginning of his first term, President Trump has recognized the incredible potential of drones to boost American productivity, create high-skilled jobs and meet national needs in areas like public safety, infrastructure, inspection, agriculture and more. But, for too long, red tape has hindered homegrown drone innovation, restricting commercial drone use and burdening their development." Duffy Contrasts Biden-era 'Drone Fiasco' With Trump Admin's 'Radical Transparency' After Faa Announces Testing Kratsios said the same about supersonic aviation, noting "Americans should be able to fly from New York to LA in under four hours." Read On The Fox News App Besides promoting innovation, the orders seek to shore up American airspace sovereignty. This directive is aimed at not only addressing potentially criminal or terror-related threats. It also aims to increase penalties for and reduce the prevalence of drone misuse in American airspace. "The president week one wanted us to take this issue seriously because of the national fury over the events over New Jersey," Sebastian Gorka, senior director of counterterrorism on the Trump administration's National Security Council, said of the new executive orders signed Friday. "For far too many years, we have not had a requisite, necessary federal response — not only to the dominance of non-U.S. platforms in this field, but also protecting sensitive sites, military sites, critical infrastructure, but also just sporting events, mass events." Rebecca Grant: America Has A Drone Problem, And No One Is In Charge White House officials who advised the president on these new executive orders said there will be more protection for critical infrastructure for sporting venues as a result of the new directives, including the upcoming FIFA World Cup. They will also enable "routine beyond visual line of sight commercial operations," such as drone deliveries, infrastructure maintenance and emergency response to incidents like wildfires. The orders will also reduce the United States' reliance on foreign countries for drone and other aviation technology, officials added. "These executive orders will accelerate American innovation in drones, flying cars and supersonic aircraft and chart the future of America's skies for years to come," Kratsios said. "Our message is simple. American innovation belongs in American aerospace."Original article source: Trump signs new executive orders intended to make flying cars a reality, slash flight times

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store